Description

Pegsebrenatide (NLY01) is a long-acting GLP-1R agonist. Pegsebrenatide has an extended half-life and favorable blood-brain barrier penetration. Pegsebrenatide can block A1 astrocyte transformation, reducing dopaminergic cell death, and improving motor symptoms in mouse models of PD[1].—–C206H318N54O69S2(C2H4O)m+2n; m≈10; n≈20—-[1]Jacob K Sterling, et al.GLP-1 Receptor Agonist NLY01 Reduces Retinal Inflammation and Neuron Death Secondary to Ocular Hypertension. Cell Rep. 2020, 33, 5.–2243292-26-2–N/A—-[Pegsebrenatide]–Neurological Disease–10 mM in DMSO–GCGR—-GPCR/G Protein–Peptides